Business Context and Reporting Period
This Form 8-K filing by Collegium Pharmaceutical, Inc. was submitted on May 14, 2015. The report details corporate governance actions taken by the Board of Directors regarding executive compensation adjustments and stock option grants effective on the same date.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
| Executive Officer | Adjusted Annual Base Salary | Cash Bonus Eligibility | Stock Options Granted |
|---|---|---|---|
| Michael T. Heffernan (CEO) | $488,800 | 50% | 70,193 shares |
| Paul Brannelly (CFO) | $325,000 | 35% | 22,929 shares |
Option Terms: The exercise price for the granted options is $14.90 per share, based on the closing stock price on the grant date. Vesting occurs over a four-year period, with 25% vesting on the first anniversary and the remainder in equal monthly installments.
Material Changes
The filing reports specific adjustments to the annual base salary and cash bonus eligibility for the CEO and CFO, effective May 14, 2015. Additionally, new stock option grants were issued to these officers under the Amended and Restated 2014 Stock Incentive Plan.
Guidance, Outlook, and Risks
The filing text does not provide financial guidance, future outlook, management commentary on business performance, or specific risk factors. The document is limited to reporting the compensation adjustments and option grants.
Key Facts for Investor Verification
- Verify the impact of the increased executive compensation on the company's cash burn rate and overall operating expenses.
- Confirm the dilution effect of the 93,122 total new stock options granted to the CEO and CFO.
- Review the vesting schedule to understand the retention timeline for key executives.
- Check the current stock price relative to the $14.90 exercise price to assess the immediate value of the grants.